These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 33912248)

  • 1. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
    Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy.
    Anjohrin S; Sheahan A; Suruki R; Stark JL; Sloan VS
    Rheumatol Ther; 2021 Dec; 8(4):1651-1659. PubMed ID: 34491550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevalence and treatment of rheumatological adverse events due to immune checkpoint inhibitor therapy].
    Verspohl SH; Schulze-Koops H; Heine A; Schäfer VS
    Z Rheumatol; 2020 Oct; 79(8):797-808. PubMed ID: 32926217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
    Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
    Front Oncol; 2021; 11():749064. PubMed ID: 34900695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
    Mathias K; Rouhani S; Olson D; Bass AR; Gajewski TF; Reid P
    Oncologist; 2023 May; 28(5):440-448. PubMed ID: 36595378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy.
    Lusa A; Alvarez C; Saxena Beem S; Schwartz TA; Ishizawar R
    BMC Rheumatol; 2022 Nov; 6(1):64. PubMed ID: 36345032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
    Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
    BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
    Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapy.
    Isaacs DJ; Kathuria-Prakash N; Hilder R; Lechner MG; Drakaki A
    Curr Cancer Rep; 2024 Feb; 5(1):168-180. PubMed ID: 39397890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis and evaluation of factors contributing to the occurrence of immune-related adverse events with immune checkpoint inhibitors.
    Nagase T; Shima O; Maruhana N; Miyazawa Y; Yoshino S; Sato J; Yamada H; Shinozaki K; Ikeda K
    Pharmazie; 2024 Aug; 79(7):163-168. PubMed ID: 39152557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
    Zhong H; Zhou J; Xu D; Zeng X
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis.
    Zhang S; Zhou Z; Wang L; Li M; Zhang F; Zeng X
    Ther Adv Chronic Dis; 2021; 12():2040622320976996. PubMed ID: 33633822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer.
    Melia A; Fockens E; Sfumato P; Zemmour C; Madroszyk A; Lafforgue P; Pham T
    Joint Bone Spine; 2023 Jan; 90(1):105457. PubMed ID: 36116771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
    Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
    Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018.
    Molina GE; Zubiri L; Cohen JV; Durbin SM; Petrillo L; Allen IM; Murciano-Goroff YR; Dougan M; Thomas MF; Faje AT; Rengarajan M; Guidon AC; Chen ST; Okin D; Medoff BD; Nasrallah M; Kohler MJ; Schoenfeld SR; Karp Leaf RS; Sise ME; Neilan TG; Zlotoff DA; Farmer JR; Mooradian MJ; Bardia A; Mai M; Sullivan RJ; Semenov YR; Villani AC; Reynolds KL
    Oncologist; 2021 Jun; 26(6):514-522. PubMed ID: 33655682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.